ArticleThe Journal of clinical and aesthetic dermatology2021
Botulinum Toxin: An Effective Treatment for Flushing and Persistent Erythema in Rosacea.
Article in The Journal of clinical and aesthetic dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
- Efficacy and safety of intradermal botulinum toxin A for post-acne erythema: a split-face randomized controlled trial.Frontiers in medicine · 2025Trial
- IncobotulinumtoxinA Injection to Balance Eyebrows and Facial Shapes: A Review with Illustrative Clinical Examples.Toxins · 2026Review
- Targeting Neurovascular Inflammation in Rosacea: A Systematic Review of Botulinum Toxin Therapy.Cureus · 2026Review
- Botulinum Toxin Vascular Effectiveness: Low or High Doses?Aesthetic plastic surgery · 2026Review
- LetibotulinumtoxinA for Rosacea: A Pilot Study.Toxins · 2026Article
- Aesthetic medicine treatments in reducing the effects of chronic demodicosis.Parasitology research · 2025Article
- Article
- A Case Series of a Novel Approach in the Treatment of Rosacea: Use of Botulinum Toxin and Intense Pulsed Light for the Treatment of Erythematotelangiectatic Rosacea.Journal of cosmetic dermatology · 2025Article
- A Review of the Diagnostic and Therapeutic Gaps in Rosacea Management: Consensus Opinion.Dermatology and therapy · 2024Article
- The Efficacy and Safety of Botulinum Toxin A for the Treatment of Rosacea: A Systematic Review.Cureus · 2023Review
- Insights on Skin Quality and Clinical Practice Trends in Asia Pacific and a Practical Guide to Good Skin Quality from the Inside Out.The Journal of clinical and aesthetic dermatology · 2022Review
- Anatomical Exhortations of Botulinum Toxin Injections for Rosacea.The Journal of clinical and aesthetic dermatology · 2022Article
- Role of Botulinum Toxin in the Management of Topical Corticosteroid Induced Rosacea Like Dermatitis: A Case Report.Indian dermatology online journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Botulinum toxin has been used to treat persistent erythema and flushing in rosacea for several years. Here, we describe two women and one man, each with rosacea with flushing and permanent erythema refractory to conventional treatment, who achieved satisfactory and lasting results following intradermal application of botulinum toxin. Two different botulinum toxin types were used. Toxin concentrations of 3.75U per 0.1 mL (abobotulinum) and 1.25U per 0.1 mL (incobotulinum) were used for each patient were used for each patient. The outcomes were measured using polarized photography to evaluate the decrease in vascular involvement. In the three cases presented here, botulinum toxin was effective for controlling erythema and flushing associated with rosacea; we also observed a prolonged duration of these improvements without the rebound effect of topical therapies.
Indexed as
Identifiers
33841616PMC8021409W3154429928What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.